Gene-Editing Companies Hit Back at Paper That Criticizes CRISPR

June 13, 2017

(MIT Technology Review) – Two gene-editing companies are hitting back at a scientific publication that caused their stocks to plummet last week, calling it wrong, filled with errors, and saying it shouldn’t have been published. In separate letters sent to Nature Methods, scientists from Intellia Therapeutics and Editas Medicine criticized a report in the journal that claimed the gene-editing tool CRISPR had caused unexpected mutations in the genomes of mice and which cast a shadow over efforts to initiate human studies using the technique.

Recommended Reading